Buy or sell guide
Should I Buy MRK Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Merck & Co., Inc..
Updated 2026-06-22
Wall Street currently rates MRK buy with a 12-month price target of $132 (+15.6% upside). The sections below cover the bull case, key risks, and latest earnings context for MRK.
Wall Street
Buy37 analystsConsensus target
$132 target (+15.6%)Current price $115.46Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 12.9%Reported Thu Apr 30Wall Street verdict
Should I Buy MRK Stock? Here's What Analysts Think
37 analysts currently cover MRK. Below is their consensus rating, price target range, and implied upside.
According to 37 analysts, Merck & Co., Inc. (MRK) is rated Buy with a consensus 12-month price target of $132 — representing 16% upside from today's price of $115. The bull case target is $150, the bear case is $100.
MRKBuy
From 37 analyst ratings- Current price
- $115.46
- Consensus Target
- $132 (+15.6% upside)
- Forward P/E
- 22.2x
- Coverage
- 37 analyst ratings
High target$150
Low target$100
At $115.46, the consensus setup implies +15.6% versus the 12-month target.
- 25 of 37 analysts lean Buy or Strong Buy, while 11 stay on Hold and 1 lean bearish.
- MRK trades at roughly 22.2x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $100 to $150, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for MRK right now.
Analyst ratings update weekly. Get MRK's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Live commentary on X
What Analysts Are Saying About Merck & Co., Inc. Right Now
Real posts from high-reach stock analysts mentioning MRK, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about MRK in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy MRK?
Is MRK a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for MRK before you decide whether to buy, hold, or sell.
Current setup
MRK beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Earnings GrowthMerck has achieved an annual earnings growth of 16.8% over the last five years, outpacing revenue growth.
- Robust Pipeline PotentialManagement projects over $70 billion in commercial opportunities by the mid-2030s, with key drugs like Welireg showing strong growth.
- Attractive Valuation MetricsMerck's P/E ratio stands at 14.8x, below the industry average, and offers a dividend yield of 3.11%.
- Substantial Free Cash Flow GrowthFree cash flow is projected to more than double in 2026, indicating strong financial health.
Wall Street rates MRK buy, giving the bull case institutional backing from 37 analysts.
Watch Out For
What can break the setup quickly
- Heavy Keytruda DependenceKeytruda accounts for roughly half of Merck's revenue, raising concerns about earnings impact post-2028 patent loss.
- Potential Overvaluation RisksSome DCF analyses suggest fair value prices significantly lower than the current trading price, indicating possible overvaluation.
- Bearish Technical IndicatorsRecent technical analysis shows bearish signals, including a 10-day moving average crossing below the 50-day moving average.
- Declining 2026 Earnings OutlookMerck's projected EPS for 2026 has been revised downward due to higher M&A charges and a drop in Gardasil sales.
Watch whether new negative commentary on MRK points to these structural risks or is simply reacting to short-term price moves.
MRK Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $-1.28 vs $-1.47 est.Beat 12.9%
- Revenue
- $16.3B vs $15.8B est.Beat 2.8%
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into MRK consensus models and risk factors.
View Analysis
Should I Buy MRK?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MRK — Frequently Asked Questions
Quick answers to the most common questions about buying MRK stock.
Should I buy MRK stock right now?
Verdict
MRK has modest upside — analysts rate it "Buy" with a $132 target, implying +15.6% from today's $115.46. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy MRK?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +15.6% upside to the $132 target.
What is the price target for MRK stock?
Price Target
MRK's consensus 12-month price target is $132, set by 37 Wall Street analysts. The bull case high is $150 and the bear case low is $100. From the current price of $115.46, this implies +15.6% upside.
Is MRK overvalued or undervalued?
Valuation
MRK appears undervalued — the $132 consensus target is +15.6% above today's $115.46. It trades at a forward P/E of 22.2x. Targets range from $100 (bear) to $150 (bull), reflecting different assumptions about growth and margins.
Should I buy MRK before earnings?
Earnings
MRK reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $132 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about MRK stock?
Coverage
Of 37 analysts covering Merck & Co., Inc. (MRK): 0 Strong Buy, 25 Buy, 11 Hold, 1 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $132 (range $100–$150). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying MRK stock?
Risks
1 of the 37 analysts covering MRK rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Merck & Co., Inc..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.